Q-omics provides the consensus-scored ATXN7 profile across patient tissues and cancer cell-line models. ATXN7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ATXN7 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ATXN7 RNA expression shows 21,444 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, THCA, and ACC as cancer lineages where ATXN7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATXN7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATXN7 survival associations across molecular data types. ATXN7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (12) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATXN7 RNA expression–survival associations across cancer types. High ATXN7 expression shows unfavorable associations in ACC, but favorable associations in HNSC, BRCA, SKCM, LUAD and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ATXN7 RNA expression.
This table summarizes ATXN7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ATXN7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATXN7 shows lower tumor expression in THCA, LUSC, KIRC and COAD and higher tumor expression in CHOL and PRAD. The THCA box plot shows higher ATXN7 RNA expression in normal versus tumor tissue (log2 FC = −0.503, t-test p < 0.001).
This table shows molecular features associated with ATXN7 in patient tissues and cancer cell lines. In patient samples, ATXN7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATXN7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
